Methods of detecting mutations associated with ataxia-ocular apraxia 2 (aoa2)

Abstract

Methods of identifying polymorphisms associated with ataxia-ocular apraxia 2 (AOA2), are described. The polymorphisms associated with AOA2 include specific mutations in the senataxin (SETX) gene. Also described are methods of diagnosis of AOA2, as well as methods of assessing an individual for carrier status for AOA2.

What is claimed is: 
     
         1 . A method of assessing an individual for the presence or absence of a genetic polymorphism associated with ataxia-ocular apraxia 2 (AOA2), the method comprising assessing a test sample from the individual for the presence of at least one mutation of interest in the senataxin (SETX) gene, wherein the mutation of interest is selected from the group consisting of:
 a) a 4 base deletion of nucleotides 369-372;   b) a 2 base insertion of AT between nucleotides 2747-2748;   c) a single base transition C→T at nucleotide 4234;   d) a single base transition C→T at nucleotide 4816;   e) a 6 base deletion of nucleotides 4873-4878 accompanied by an insertion of GG at the same location;   a single base insertion of G between nucleotides 4891-4892;   g) a 2 base insertion of CA between nucleotides 5301-5302;   h) a 4 base deletion of nucleotides 5308-5311;   i) a 2 base deletion of nucleotides 5591-5592;   j) a single base deletion of nucleotide 5958;   k) a single base insertion of A between nucleotides 6422-6423;   l ) a single base transition C→T at nucleotide 6292;   m) a four base deletion of nucleotides 6848-6851;   n) a single base insertion of T between nucleotides 479-480;   o) a 4 base deletion of nucleotides 4633-4636; and   p) a 2 base deletion of nucleotides 6114-6115,   wherein the presence of at least one mutation of interest is indicative of the presence of a genetic polymorphism associated with ataxia-ocular apraxia 2.   
     
     
         2 . The method of  claim 1 , wherein the test sample from the individual comprises genomic DNA. 
     
     
         3 . The method of  claim 2 , wherein the genomic DNA comprises chromosome 9 or a fragment thereof comprising 9q34. 
     
     
         4 . The method of  claim 1 , wherein assessing the test sample comprises amplifying all or a fragment of the senataxin gene. 
     
     
         5 . The method of  claim 1 , wherein assessing the test sample comprises direct sequence analysis. 
     
     
         6 . A method of diagnosing ataxia-ocular apraxia 2 (AOA2) in an individual, comprising assessing a test sample from the individual for the presence of at least one mutation of interest in a first allele of the senataxin (SETX) gene of the individual, wherein the mutation of interest is selected from the group consisting of:
 a) a 4 base deletion of nucleotides 369-372;   b) a 2 base insertion of A between nucleotides 2747-2748;   c) a single base transition C→T at nucleotide 4234;   d) a single base transition C→T at nucleotide 4816;   e) a 6 base deletion of nucleotides 4873-4878 accompanied by an insertion of GG at the same location;   a single base insertion of G between nucleotides 4891-4892;   g) a 2 base insertion of CA between nucleotides 5301-5302;   h) a 4 base deletion of nucleotides 5301-5311;   i) a 2 base deletion of nucleotides 5591-5592;   j) a single base deletion of nucleotide 5958;   k) a single base insertion of A between nucleotides 6422-6423;   l ) a single base transition C→T at nucleotide 6292;   m) a four base deletion of nucleotides 6848-6851;   n) a single base insertion of T between nucleotides 479-480;   o) a 4 base deletion of nucleotides 4633-4636; and   p) a 2 base deletion of nucleotides 6114-6115,   wherein the presence of a mutation of interest in the first allele of the senataxin gene is indicative of ataxia-ocular apraxia 2 if at least one mutation associated with ataxia-ocular apraxia 2 is also present in the second allele of the senataxin gene.   
     
     
         7 . The method of  claim 6 , wherein both the first and the second alleles of the senataxin (SETX) gene comprise at least one mutation of interest selected from the group consisting of:
 a) a 4 base deletion of nucleotides 369-372;   b) a 2 base insertion of AT between nucleotides 2747-2748;   c) a single base transition C→T at nucleotide 4234;   d) a single base transition C→T at nucleotide 4816;   e) a 6 base deletion of nucleotides 4873-4878 accompanied by an insertion of GG at the same location;   f) a single base insertion of G between nucleotides 4891-4892;   g) a 2 base insertion of CA between nucleotides 5301-5302;   h) a 4 base deletion of nucleotides 5308-5311;   i) a 2 base deletion of nucleotides 5591-5592;   j) a single base deletion of nucleotide 5958;   k) a single base insertion of A between nucleotides 6422-6423;   l ) a single base transition C→T at nucleotide 6292;   m) a four base deletion of nucleotides 6848-6851;   n) a single base insertion of T between nucleotides 479-480;   o) a 4 base deletion of nucleotides 4633-4636; and   p) a 2 base deletion of nucleotides 6114-6115.   
     
     
         8 . The method of  claim 7 , wherein both the first and the second alleles of the senataxin gene comprise the same mutation(s). 
     
     
         9 . The method of  claim 6 , wherein the test sample from the individual comprises genomic DNA. 
     
     
         10 . The method of  claim 9 , wherein the genomic DNA comprises chromosome 9 or a fragment thereof comprising 9q34. 
     
     
         11 . The method of  claim 6 , wherein assessing the test sample comprises amplifying all or a fragment of the senataxin gene. 
     
     
         12 . The method of  claim 6 , wherein assessing the test sample comprises direct sequence analysis. 
     
     
         13 . A method of assessing an individual for carrier status for ataxia-ocular apraxia 2 (AOA2), the method comprising assessing a test sample from the individual for the presence of a mutation of interest in first and second alleles of the senataxin (SETX) gene of the individual, wherein the mutation of interest is selected from the group consisting of:
 a) a 4 base deletion of nucleotides 369-372;   b) a 2 base insertion of AT between nucleotides 2747-2748;   c) a single base transition C→T at nucleotide 4234;   d) a single base transition C 43  T at nucleotide 4816;   e) a 6 base deletion of nucleotides 4873-4878 accompanied by an insertion of GG at the same location;   a single base insertion of G between nucleotides 4891-4892;   g) a 2 base insertion of CA between nucleotides 5301-5302;   h) a 4 base deletion of nucleotides 5308-5311;   i) a 2 base deletion of nucleotides 5591-5592;   j) a single base deletion of nucleotide 5958;   k) a single base insertion of A between nucleotides 6422-6423;   l ) a single base transition C→T at nucleotide 6292;   m) a four base deletion of nucleotides 6848-6851;   n) a single base insertion of T between nucleotides 479-480;   o) a 4 base deletion of nucleotides 4633-4636; and   p) a 2 base deletion of nucleotides 6114-6115,   wherein the presence of the mutation of interest in the first allele of the senataxin gene, and the absence of any mutation associated with ataxia-ocular apraxia 2 in the second allele of the senataxin gene, is indicative of carrier status for ataxia-ocular apraxia 2.   
     
     
         14 . The method of  claim 13 , wherein the test sample from the individual comprises genomic DNA. 
     
     
         15 . The method of  claim 14 , wherein the genomic DNA comprises chromosome 9 or a fragment thereof comprising 9q34. 
     
     
         16 . The method of  claim 13 , wherein assessing the test sample comprises amplifying all or a fragment of the senataxin gene. 
     
     
         17 . The method of  claim 13 , wherein assessing the test sample comprises direct sequence analysis.